A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf.
Conditional approval of sunitinib
2007
EJC Supplements
Preserved Fulltext
Sunitinib malate (Sutent) is a small molecule ATP site-directed competitive inhibitor. It inhibits multiple processes necessary for tumour growth, including tumour cell proliferation and angiogenesis, through its action on multiple receptor tyrosine
doi:10.1016/j.ejcsup.2007.09.041
fatcat:k66xcqv42bcfzl37mwah44mcfa